ACER News and Press, Acer Therapeutics Inc. From 04/04/22

NEWTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...

Nasdaq Stock Market informed Acer Therapeutics (NASDAQ:ACER) that it has regained compliance with the minimum market value of listed securities for continued listing on the Nasdaq Capital Market. It was notified in December 2021 that it had failed to maintain a minimum market value of li...

NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...

NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...

SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021 PR Newswire Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board an...

Acer Therapeutics (NASDAQ:ACER) entered into convertible note and loan financing facilities for up to $48.5M with affiliates of Marathon Asset Management and SWK. With Marathon, it has $6M secured convertible note which would have a 3-year term, bear annual interest at 6.5%; with SWK, it...

NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...

Acer Therapeutics press release (NASDAQ:ACER): Q4 GAAP EPS of -$0.31 misses by $0.30. Revenue of $0.36M misses by $2.97M. Ended Q4 2021 with $12.7 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of December 31, 2021. For further details see: ...

NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported f...

NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced th...